Some anti-oxidants have been researched for both treatment of viruses and cancer, but it is not yet a standard or widely accepted treatment, and more research is needed to evaluate the efficacy and impact on chronic disease. However, there are some remarkable case studies of a few patients with this regimen. Some anti-oxidants have shown potential in cancer prevention attributed to their anti-oxidant and anti-inflammatory properties, and maintaining the homeostasis of the immune system. There are case studies of patients with hepatitis C (which can lead to liver cancer), that have complete resolution of their virus with the triple anti-oxidant therapy

Alpha-lipoic acid (ALA) is a compound made in the cell mitochondria- the power houses of the cell. It can potentially enhance immune function, effecting the mechanisms in tumor prevention and anti-cancer activity.

In the below listed scientific article, there is significant research describing the ALA effects on the proliferation of cancer cells, targeting of downstream pathways of cancer cell proliferation, the promotion of tumor suppressor proteins, curb the signaling pathway affecting tumor metastasis, and limit the abilities of cancer stem cells. Maintenance dose of 300 mg twice a day.

Silymarin is found in milk thistle, and has both anti-oxidant and anti-inflammatory properties that may protect against viral damage. Several viruses can cause cancer (10-13% of cancers), some directly (oncoviruses) and some indirectly via chronic inflammation or by weakening the immune system. Maintenance dose of 300 mg three to four times per day, depending on the study reviewed.

Selenium (selenomethionine) is an essential mineral that plays a role in immune function and may have antiviral properties. Maintenance dosage of 200 ucg one to two times a day, depending on the study reviewed.

Glutathione is an antioxidant that is made in the body that is associated with white blood cell leukocyte proliferation, enhanced immune system function, and effective antiviral protection.

Low dose naltrexone (LDN) is a non-selective antagonist of opioid receptors, primarily used in the therapy of opioid and alcohol dependence. LDN impacts the survival, proliferation and invasion of cancer cells, and has been used in combination with anti-oxidant therapy in some case reports, as well as been suggested as an adjuvant in chemotherapy and immunotherapy for cancerous lesions. It is typically prescribed as 4.5 mg at night.

​